Olema Oncology (OLMA) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026OPERA-01 design and readout
OPERA-01, a Phase III monotherapy trial in 2L/3L metastatic breast cancer after CDK4/6 + AI, compares once-daily palazestrant with fulvestrant or exemestane; PFS is the primary endpoint, with readout expected in Q1 2027.
Tumors are tested for ESR1 status and patients are stratified; mutant and wild-type populations are analyzed independently, and meeting the critical value in either population would be a positive trial.
Management said the trial is powered to detect a clinically meaningful benefit in either population; the meaningful threshold may differ with the existing standard of care.
Compared with Phase II, OPERA-01 excludes prior chemotherapy for advanced/metastatic disease and requires at least 6 months without progression on prior therapy; Phase II allowed prior chemotherapy and had no progression-time cutoff.
Management highlighted the convenience and potential quality-of-life benefit of one daily pill versus two large-volume intramuscular injections every 28 days with fulvestrant.
Efficacy rationale and market opportunity
Phase II median PFS was 7.3 months in ESR1-mutant disease and 5.5 months in wild-type disease; management cited expected control-arm PFS of 2–3 months.
Management sees potential differentiation in mutant disease and a possible wild-type benefit, which it described as unique; cited annual market opportunities were $2B for mutant and ~$3B for wild-type disease.
Management said prior SERD results established activity in ESR1-mutant disease, while wild-type activity has been harder to demonstrate; OPERA-01 tests the two groups separately.
Management distinguished OPERA-01’s endocrine-resistant population, after CDK4/6 + AI, from endocrine-sensitive patients in OPERA-02, cautioning that outcomes in one setting may not predict the other.
First-line and future development
OPERA-02, a Phase III first-line study with palazestrant plus KISQALI, is enrolling well; KISQALI + AI is the control regimen and the global standard of care.
Management plans to assess SERENA-4 data expected in early December 2026 for a current estimate of control-arm performance; a longer-than-expected control PFS could prompt a trial modification.
After the OPERA-01 readout, management said an adjuvant palazestrant trial would be worth considering and that the result would help inform future strategy.
Latest events from Olema Oncology
- Palazestrant’s Q1 OPERA-01 readout tests PFS in both ESR1-mutant and wild-type disease.OLMA
Jefferies Global Healthcare Conference - Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025